Lumen Bioscience, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2017-04-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.lumen.bio
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
Early Phase 1
Recruiting
- Conditions
- Travelers Diarrhea
- Interventions
- Biological: LMN-401
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06556940
- Locations
- π¦πΊ
Coastal Digestive Health Research Institute Pty Ltd, Maroochydore, Australia
Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
Recruiting
- Conditions
- Travelers Diarrhea
- Interventions
- Diagnostic Test: TAQMan Array Card
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT06363890
- Locations
- π¦πΊ
AK Clinical Research, Melbourne, Australia
A Study to Determine the Tolerability of Intranasal LMN-301
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: LMN-301
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06030414
- Locations
- π¦πΊ
CMAX Clinical Research, Adelaide, South Australia, Australia
LMN-201 for Prevention of C. Difficile Infection Recurrence
Phase 2
Recruiting
- Conditions
- Clostridioides Difficile Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT05330182
- Locations
- πΊπΈ
Kaiser Permanente, Los Angeles, California, United States
πΊπΈBridgeport Hospital, Bridgeport, Connecticut, United States
πΊπΈGastroenterology Center of Connecticut, Hamden, Connecticut, United States
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Phase 1
Completed
- Conditions
- C. Diff. Infections
- Interventions
- Biological: LMN-201 Anti-toxin B VHH-1Biological: LMN-201 Anti-toxin B VHH-2Biological: LMN-201 Anti-toxin B VHH-3Biological: LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04893239
- Locations
- π¦πΊ
Coral Sea Clinical Research Institute, North Mackay, Queensland, Australia
π¦πΊCoastal Digestive Health, Maroochydore, Queensland, Australia
π¦πΊWesley Medical Research Limited, Auchenflower, Queensland, Australia
LMN-101 in a Campylobacter Human Challenge Model
Phase 2
Completed
- Conditions
- Campylobacter Infections
- Interventions
- Biological: LMN-101Drug: Placebo
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04182490
- Locations
- πΊπΈ
Pharmaron, Baltimore, Maryland, United States
Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Lumen Bioscience, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04098263
- Locations
- π¦πΊ
Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
Β© Copyright 2025. All Rights Reserved by MedPath